Physician profile
Jared A Jaffe
NPI 1093709859
$18,627.59
in general payments reported to CMS, 2019-2025
50 companies · $3,425 in 2025
The $3,425 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $1,353 · 2021: $2,554 · 2022: $4,051 · 2023: $2,601 · 2024: $3,036 · 2025: $3,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,858 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,857.90 |
| Education | $204.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,489.50 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,905.35 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Opko Pharmaceuticals, LLC | $1,334.48 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $1,148.51 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $1,076.21 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $885.29 | 2021-2025 | |
| Novo Nordisk INC | $755.47 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Biomerieux INC | $724.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $666.55 | 2019-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $622.90 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $618.52 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $608.36 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $592.97 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $518.93 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $514.32 | 2019-2022 |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.